Valuation: Acrux Limited

Market Cap 6.16M 4.3M 3.78M 3.53M 3.24M 6.08M 413M 41.85M 16.37M 204M 16.16M 15.81M 705M P/E 2024
-3.44x
P/E 2025 -0.95x
Enterprise Value 8.93M 6.24M 5.49M 5.11M 4.69M 8.81M 599M 60.69M 23.74M 296M 23.43M 22.92M 1.02B EV / Sales 2024
4.09x
EV / Sales 2025 7.81x
Free-Float
78.27%
Yield 2024 *
-
Yield 2025 -
1 day-8.33%
1 week-8.33%
Current month-8.33%
1 month-21.43%
6 months-26.67%
Current year-26.67%
1 week 0.01
Extreme 0.011
0.01
1 month 0.01
Extreme 0.011
0.01
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.009
0.02
3 years 0.01
Extreme 0.009
0.1
5 years 0.01
Extreme 0.009
0.14
10 years 0.01
Extreme 0.009
0.78
Manager TitleAgeSince
Chief Executive Officer - 01/06/2025
Director of Finance/CFO - 21/06/2021
Chief Tech/Sci/R&D Officer - 15/02/2015
Director TitleAgeSince
Chairman 74 01/01/2006
Director/Board Member - 01/10/2013
Director/Board Member 70 01/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
-8.33%-8.33%-38.89%-77.55% 4.31M
+1.68%+2.13%+16.17%+77.49% 48.36B
+1.52%+2.95%+60.39%+112.28% 35.8B
-0.09%-0.66%-8.03%+31.90% 11.83B
-0.05%-3.10%+13.50%+77.95% 11.48B
-0.37%-0.37%+37.53%+142.08% 9.01B
+0.18%+0.58%+49.62%-9.13% 6.99B
+0.95%-2.00%+12.78%+32.58% 6.7B
+0.18%-1.77%+2.36%+172.36% 6.42B
+3.51%-10.57%-31.55%+0.09% 5.3B
Average -0.08%-1.09%+11.39%+56.01% 14.19B
Weighted average by Cap. +1.11%-0.14%+25.52%+81.62%

Financials

2024 2025
Net sales 5.09M 3.56M 3.13M 2.91M 2.67M 5.02M 341M 34.6M 13.53M 168M 13.35M 13.07M 583M 1.19M 832K 731K 681K 625K 1.17M 79.75M 8.09M 3.16M 39.37M 3.12M 3.05M 136M
Net income -5.8M -4.05M -3.56M -3.32M -3.05M -5.72M -389M -39.41M -15.42M -192M -15.21M -14.89M -664M -5.94M -4.15M -3.65M -3.4M -3.12M -5.87M -398M -40.4M -15.81M -197M -15.59M -15.26M -680M
Net Debt 759K 530K 466K 434K 399K 749K 50.86M 5.16M 2.02M 25.11M 1.99M 1.95M 86.84M 2.77M 1.94M 1.7M 1.59M 1.46M 2.74M 186M 18.84M 7.37M 91.72M 7.27M 7.11M 317M
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume
27/07/26 A$0.0110 -8.33% 169,956
24/07/26 A$0.0120 0.00% 30,408
23/07/26 A$0.0120 0.00% 111,592
22/07/26 A$0.0120 0.00% 339
21/07/26 A$0.0120 0.00% 700,000

Annual profits - Rate of surprise